A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Jun 2018
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms SAXAPCOS
- 12 Jun 2018 Planned primary completion date changed from 8 Jul 2020 to 8 Sep 2020.
- 12 Jun 2018 Planned initiation date changed from 2 Jul 2018 to 2 Sep 2018.
- 29 Mar 2018 New trial record